Botulinum toxin is a treatment whose effectiveness has been widely demonstrated in the treatment of facial wrinkles. Its use in alopecia has been much less studied in the literature. Therefore, we carried out a systematic review of the literature in December 2019 in order to index published cases of alopecia patients treated with botulinum toxin. Pub Med, Embase, and Cochrane Library databases were explored. Six studies that included 94 patients were selected. Only one study was prospectively controlled against placebo. Of the 94 patients, 85 were affected by androgenetic alopecia, 8 by alopecia areata, and 1 by radiation-induced alopecia. The doses injected per session varied between 30 and 150 units and the number of sessions between 1 and 12. In the majority of the studies, the injections were carried out in all the muscles of the scalp (frontal, temporal, peri-auricular, occipital). Four studies showed a frank improvement in hair growth. Two of them showed improvement in hair density using an objective endpoint (hair count). The remaining reported studies showed inconclusive results. Patient satisfaction was high across all studies, but this systematic review did not clearly demonstrate the value of using the botulinum toxin in the treatment of alopecia. Subsequent prospective randomized controlled studies are required.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bjps.2020.05.035 | DOI Listing |
Pain Pract
February 2025
Department of Anesthesiology and Pain Management, Leiden University Medical Center, Leiden, The Netherlands.
Introduction: Pain from the cervical facet joints, either due to degenerative conditions or due to whiplash-related trauma, is very common in the general population. Here, we provide an overview of the literature on the diagnosis and treatment of cervical facet-related pain with special emphasis on interventional treatment techniques.
Methods: A literature search on the diagnosis and treatment of cervical facet joint pain and whiplash-associated disorders (WAD) was performed using PubMed, Cochrane, and Embase databases.
Urogynecology (Phila)
February 2025
From the Departments of Gynecology and Obstetrics.
Importance: Patients deciding between advanced therapies for overactive bladder syndrome may be interested to know the likelihood of treatment crossover after sacral neuromodulation, intradetrusor OnabotulinumtoxinA, or percutaneous tibial nerve stimulation. Treatment crossover was defined as a switch from one advanced therapy to another.
Objectives: The aim of this study was to estimate the rate of treatment crossover after each advanced therapy for nonneurogenic overactive bladder syndrome.
Dermatol Surg
January 2025
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P.R. China.
Background: Androgenetic alopecia (AGA) is a prevalent condition that significantly affects the psychosocial well-being of many individuals, and its treatment remains a clinical challenge. Botulinum toxin (BTX) injections have been reported to have a therapeutic effect on AGA. Although several studies have explored the efficacy and safety of this novel treatment, most are clinical studies with small sample sizes.
View Article and Find Full Text PDFDermatol Surg
January 2025
All authors are affiliated with the Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: The application of randomized controlled trials (RCTs) outcomes of botulinum toxin type A (BoNT-A) to actual patient care faces a significant hurdle due to research waste (RW). This includes the results of RCTs that have not been published even 4 years after completion and those with insufficiently reported outcomes and design flaws. The prevalence of RW within BoNT-A-associated RCTs remains uncertain.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece.
Objective: NCTF135HA, a versatile polyrevitalizing solution, is a potent agent for enhancing skin quality, radiance, moisture, vitality, and diminishing fine wrinkles caused by aging factors. Data demonstrate a divergence in its application from skin quality enhancement to treatment of vitiligo lesions. To know more precisely about the protocol of use among providers, alone or in combination with other procedures, we performed an international survey.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!